OTIC News and Press, Otonomy Inc. From 12/23/19

Oppenheimer starts Otonomy (NASDAQ: OTIC ) with an Outperform rating and $8 price target, a 217% upside. The company has a Very Bullish average Sell Side rating . More news on: Otonomy, Inc., Healthcare stocks news, Stocks on the move, Read more ...

The following slide deck was published by Otonomy, Inc. in conjunction with their 2019 Q3 earnings Read more ...

Otonomy, Inc. (OTIC) Q3 2019 Earnings Conference Call November 5, 2019 4:30 PM ET Company Participants Stephen Jasper – Westwicke Partners David Weber – President and Chief Executive Officer Paul Cayer – Chief Financial and Business Officer. Conference Cal...

Otonomy (NASDAQ: OTIC ): Q3 GAAP EPS of -$0.33 beats by $0.12 . More news on: Otonomy, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™  in Ménière’s disease Broadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common cause of congenital hearing...

SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2019 as well as provide a corporate upd...

GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, ...

SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the 2019 C...

SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413, a sustained-exposure formulation of ...

Otonomy, Inc. (OTIC) Q2 2019 Earnings Conference Call August 1, 2019 4:30 PM ET Company Participants Stephen Jasper – Westwicke Partners David Weber – President and Chief Executive Officer Paul Cayer – Chief Financial and Business Officer Conference Call P...